Adipose tissue dysfunction is an important determinant of obesity-associated lipid induced metabolic complications. Ceramides are well known mediators of lipid induced insulin resistance in peripheral organs such as muscle. DEGS1 is the desaturase catalysing the last step in the main ceramide biosynthetic pathway. Functional suppression of DEGS1 activity results in substantial changes in ceramide species likely to affect fundamental biological functions such as oxidative stress, cell survival and proliferation. Here, we show that degs1 expression is specifically decreased in the adipose tissue of obese patients and murine models of genetic and nutritional obesity.
Dysfunction of white adipose tissue (WAT) and impaired differentiation of new adipocytes may lead to lipid leakage and inappropriate accumulation of ectopic lipids in peripheral organs, causing lipotoxicity and the Metabolic Syndrome (1) . The toxic effects of lipids are determined by both the quantity and also by their qualitative characteristics (2) . Whereas it is well documented that specific species of sphingolipids and ceramides mediate lipotoxicity in liver and muscle (3; 4) , the contribution of specific lipotoxic species to WAT dysfunction in the context of obesity is still not well defined.
It is known that in rodent WAT, ceramides increase in response to HFD (5; 6) concomitantly with the onset of insulin resistance (6) . Lipid analysis of WAT from human obese subjects has produced conflicting results, showing either increased or decreased ceramide levels in obese and insulin resistant patients (7; 8) .
Ceramides can be synthesised from sphingomyelins, but the main contributor to their biosynthesis is the de novo pathway. The final reaction of the de novo pathway is catalyzed by a ∆4-dihydroceramide desaturase (DEGS1) that adds a 4,5-trans-double bound on the sphingoid base of the dihydroceramide (DhCer) (9) . The other enzyme, DEGS2 catalyzes the synthesis of phytoceramides (10) , whose expression is restricted to skin, intestine and kidney.
There is evidence that downregulation of degs1 increases the DhCer/Cer ratio in different cellular models. Although DhCer was considered an inactive precursor of ceramides (11) , recent studies have suggested their relevance as modulators of cell cycle, apoptosis, autophagy or oxidative stress (12; 13) , processes that a priori are expected to compromise the development and function of adipose tissue.
Since DEGS1 is the key enzyme regulating the DhCer/Cer ratio, understanding its regulation is important in determining the pathophysiological relevance of this pathway in adipose tissue. Of note, degs1 has recently been identified in a GWAS study as a
Page 3 of 42 Diabetes
candidate gene associated with fat mass accumulation in mice (14) further suggesting that DEGS1 may be relevant for the adaptive accretion of adipose tissue. Moreover, DEGS1 could be considered an attractive therapeutic target for obesity-associated insulin resistance, since Fenretinide has been claimed to improve insulin sensitivity by inhibiting DEGS1 (15) , although other molecular targets cannot be ruled out.
Here we show that DEGS1 expression is selectively perturbed in the WAT of murine models of nutritional and genetically induced obesity and in WAT of morbidly obese patients. In vitro analysis revealed that both pharmacological inhibition and genetic ablation of DEGS1 results in impaired adipocyte differentiation and lipid accumulation, effects mediated by increased dihydroceramide content. In vivo, pharmacological inhibition of DEGS1 also resulted in impaired adipocyte differentiation. Decreased levels of DEGS1 were associated with increased oxidative stress, accelerated cellular death and blockage of cell cycle. We also show data supporting that DEGS1 expression is regulated by PPARγ.
RESEARCH DESIGN AND METHODS

Mice husbandry
Animals were housed at 22-24°C with 12h light/dark cycles. Food and water were available ad libitum. Lean wildtype, PPARγ2 −/− and PPARγ2 −/− xob/ob mice (POKO) (16) were used for profiling purposes. Mice were placed on a normal chow diet (D12450B) or in HFD (D12451) from Research Diets.
For the pharmacological inhibition of DEGS1, 10 weeks-old male C57BL/6 WT mice were used. Mice were given a HFD for 5weeks before C8-CPPC (Matreya)
administration. All protocols used were approved by the UK Home Office.
Intraperitoneal injection of cyclopropenylceramide.
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Mice were distributed in 2 groups (n=8) and administered daily vehicle (2- hydroxypropyl betacyclodextrine) or C8-CPPC (2mg/kg/day) for 9d via intraperitoneal injection. Mice were culled at the end of the experiment and WAT| was removed for gene expression and microscopy analysis. No differences in food intake, lean mass and fat content were observed during the treatment.
Ex vivo experiments in isolated mature adipocytes
Adipocytes from gonadal WAT of 16weeks C57BL/6 mice were obtained by collagenase type II digestion at 37ºC. After digestion, adipocytes were placed in DMEM media with or without 1µM C8-CPPC every 5h for a total period of 20h.
Retroviral Short Hairpin RNA Constructs for DEGS1
A RNAi-Ready pSIREN-RetroQ vectors (BD Biosciences) were used to target degs1 in 3T3L1-cells. Sequences targeting degs1 were ligated into the pSIREN vector as described in manufacturer's instructions. Retroviruses were generated by transfecting BOSC cells (ATCC) with the pSIREN plasmids using FuGene6 (Roche). Supernatant with the viral content was used to transfect 3T3-L1 preadipocytes. 24h after retroviral infection, the cells were selected with puromycin (4µg/ml).
Culture, differentiation and treatment of 3T3-L1 preadipocytes
Cells were differentiated into adipocytes (day9) accordingly to the protocol described in (17) with or without rosiglitazone 0.1µM. Lipid accumulation was assessed by Oil red O solution (18) .
Pharmacological inhibition of DEGS1 activity in vitro.
Effects on differentiation. At day 0 of differentiation, 3T3-L1 cells were treated with C8-CPPC 1µM and/or Rosiglitazone 0.1µM for 96h.
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Effects on lipolysis.On day 8 of differentiation, after 48h treatment with C8-CPPC 1µM the cells were exposed to Noradrenaline (NA) (10 −8 M and 10 −7 M) for 6h.
Effects on insulin signalling. On day 8 of differentiation, after 48h treatment with C8-CPPC 1µM the cells were exposed to insulin (10nM and 100nM) for 15min.
Effects on glut4, adiponectin. On day 8 of differentiation, after 48h treatment with C8-CPPC 0.5-1µM the cells were exposed to insulin.
Effects on AMPK. On day 8 of differentiation, after 48h treatment with C8-CPPC 0.5-1µM the cells were exposed to insulin (10nM and 100nM), rosiglitazone (1nM and 10nM) and metformin (100nM) for 24h.
Dihydroceramide treatment.
3T3-L1 preadipocytes were treated at day 0 of differentiation with the induction cocktail and C2DhCer at 50µM for 3d, and a second batch of cells were exposed at day 3 of differentiation and treated with C2DhCer at 50µM for 3d. All batches were taken until final differentiation at day 9.
Human samples
The cohort included 28 morbidly obese (MO) and 6 non-obese subjects with no alterations to lipid or glucose metabolism, as controls (Table I) . Approval for the study was given by the ethics committee and all patients gave their informed consent. Visceral adipose tissue biopsies were obtained from MO patients undergoing bariatric surgery (Scopinaro procedure) or laparoscopic surgery (hiatus hernia repair or cholecystectomies) for the lean subjects.
Western blotting
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Cells were incubated with Bodipy at 4ºC or alternatively with 20µM DCF-DA or 100nM Mitotracker (Invitrogen) at 37°C for 30 min and analysed on a FACSCalibur.
Cellular oxygen consumption
Cells were exposed to oligomycin (1µM), C8-CPPC (0.9µM) and Antimycin/Rotenone (1µM each); O2 consumption was measured using the XF24 analyzer (Seahorse Bioscience) for a period of 90min.
Whole-mount confocal microscopy
Gonadal adipose tissue was fixed in 4% paraformaldehyde. Samples were incubated at 4°C with mouse pref-1 or rabbit Ki67 primary antibodies. Nuclei and neutral lipids were stained with Hoechst 33342, and BODIPY 493/503 respectively. Sample examination was performed using a Zeiss 510 confocal laser scanning microscope (Carl Zeiss).
Pref1, Ki67, Bodipy positive cells and total cells (up to 913 cells/field) were automatically counted by using Image J software in 3 independent fields in each tissue.
Light microscopy analysis
Samples for adipose tissue H&E staining were prepared as described elsewhere (16) .
Adipocyte sizes were measured using Cell P (Olympus soft Imaging Solutions GMBH).
Between 1000-3000 adipocytes from each mouse were used to obtain the mean cellarea.
Luciferase reporter assay
HEK293 cells were transfected using Lipofectamine LTX (Invitrogen), following the manufacturer's instructions. 75ng of the reporter plasmid (3xPPRE TKLuc) and 37.5ng of the eukaryotic expression vector (pSV-PPARγ) were cotransfected to each well. The plasmid pRL-CMV (5ng/well) was included as an internal control. 24h post transfection cells were treated as indicated (DMSO, Rosiglitazone 10µM, GW1929 10µM, C2 and C16 DhCers and Cer 100 µM). Luciferase assays were performed using the dual luciferase reporter assay system (Promega).
Lipidomics
Cells were mixed with 0.9% NaCl and sonicated for 5 min at 5 ºC, 40 kHz. Samples were spiked with internal standard (IS). The samples were extracted with chloroform:methanol (2:1). The lower phase was collected and mixed with the labeled standard mixture (three stable isotope-labeled reference compounds). Lipid extracts were analyzed on a Q-ToF Premier mass spectrometer (Waters) combined with an Acquity Ultra Performance Liquid chromatography(UPLC/MS). The data was processed using MZmine software. The lipids were quantified by normalizing with corresponding IS.
Statistical analysis
Student t-test (unpaired), ANOVA and Duncan test were used for the statistical analysis. Statistically significance was set at p<0.05 and p<0.01. Spearman correlation was calculated to estimate the linear correlations between variables p<0.01.
RESULTS
DEGS 1 is downregulated in WAT in obese murine models.
Tissue distribution analysis showed that degs1 is present in most tissues and it is particularly highly expressed in adipose tissue, liver and muscle, whereas degs2 mRNA is only detected in intestine (Fig. 1A) . Degs1 expression in vivo was positively Page 9 of 42 Diabetes correlated with WAT mass in lean healthy mice (Fig. 1B) . However, this correlation was disrupted in murine models of nutritional and genetically induced obesity (HFD and ob/ob), where degs1 mRNA expression was decreased vs. controls ( Fig.1C and 1F ).
Of note, the dysregulation of degs1 in obesity was limited to WAT, as its expression in liver or skeletal muscle was not affected in either HFD fed mice ( Fig.1D and 1E ) or in ob/ob mice ( Fig.1G and H) . DEGS1 was preferentially expressed in matured adipocytes vs. stromal vascular fraction (svf) in lean and ob/ob mice ( Fig.S1 ) and downregulated in ob/ob adipocytes vs lean adipocytes. Moreover, this downregulation of degs1 in total WAT of HFD fed and ob/ob mice was also recapitulated in visceral AT of morbidly obese patients (Fig S2A) .
To determine whether the decrease in degs1 expression was part of a global adaptation of de novo ceramide synthesis pathway in obesity, the expression of other genes in this pathway were measured. Expression of the sptlc1 and sptlc2 subunits were not changed in human visceral AT, nor in ob/ob WAT, but sptlc2 expression was increased in HFD WAT (Fig S2B-C) . Moreover, both HFD and ob/ob mouse WAT exhibited a reduction in a subset of ceramide synthases, suggests a possible defect in the synthesis of specific subset of ceramides.
We then confirmed that modulators of obesity associated inflammation may contribute to the downregulation of degs1, as treatment of 3T3-L1 adipocytes with TNFα (5 ng/ml and 10ng/ml) for 48h resulted in a dose dependent downregulation of degs1 mRNA expression (38.8±3.6% and 45.7±7.3% reduction respectively).
We then investigated a link between DEGS1 and the adipogenic programme. It is known that obese and insulin resistant murine models and humans have reduced expression of pparγ2 in WAT. Furthermore we observed that expression of pparγ2 and degs1 were directly correlated in 3T3-L1 after treatment with Rosiglitazone (Fig.S3A ).
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To validate this in vivo, we analyzed the regulation of degs1 in adipose tissue, liver and skeletal muscle of pparγ2KO and the POKO mice (16) . WAT of pparγ2KO and POKO mice expressed significantly lower degs1mRNA levels vs. wt (Fig.S3B ). This association was restricted to WAT since the expression of degs1 in other metabolic organs such as skeletal muscle or liver was not affected when pparγ2 was absent ( Fig.S3C and D) .
DEGS1 controls important cellular functions such as proliferation, survival and oxidative stress in 3T3-L1 adipocytes.
A stable degs1 knock-down 3T3-L1 cell line (65%) ( Fig.2A ) resulted in inhibition of cell growth after 24h ( Fig.2B-C) . Degs1 knock-down also induced cell death (13.7%) and apoptosis (6.3%) (Fig.2E ). These were associated with a decrease in cyclin-A and cdk2 in degs1KD proliferating cells ( 
DEGS1 is required for adipocyte differentiation.
Expression of degs1 is increased during normal differentiation of 3T3-L1 adipocytes (Fig.3A) . To investigate whether ablation of DEGS1 affected adipogenesis, 3T3-L1 degs1KD cells were induced to differentiate. At d9, degs1KD cells showed impaired lipid accumulation vs. controls (Fig.3B) . Moreover, pref1 mRNA expression, a marker for preadipocytes was not decreased in degs1KD cells at d9 suggesting that a relevant number of cells remained in the preadipocyte stage (Fig.3C ). In addition, expression of Page 11 of 42 Diabetes proadipogenic and lipogenic genes were downregulated (Fig.3D) . Interestingly, treatment with rosiglitazone only partially improved the differentiation and lipid accumulation rates of degs1KD cells ( Fig. S4A -B).
We tested whether DEGS1 expression may affect the mitotic clonal expansion (MCE).
In degs1KD cells, pparγ and cebpβ were downregulated compared to controls at time 0 and 24h following differentiation induction (Fig. S5AB ). The expression of PPARγ and several cyclins involved in adipogenesis were measured at earlier time points. We noted a strong effect of degs1 depletion on PPARγ2 mRNA from time 0. Additionally, reduced levels of degs1 blocked MCE as indicated by the inhibition of cyclin D1 and cdk2 expression between time 0 and 4h hours after the induction (Fig. S5AB) . Cyclin E and cyclin D3 expression was also inhibited but at later time points.
Pharmacological inhibition of DEGS1 recapitulates DEGS1KD antiadipogenic phenotype.
Use of C8-cyclopropenylceramide (C8-CPPC), a selective inhibitor of DEGS1 (21) further confirmed the relevance of DEGS1 in adipogenesis. Similarly to degs1KD cells, 3T3-L1 cells were induced to differentiate and treated simultaneously with C8-CPPC from time 0h every 6h for 48h. C8-CPPC decreased the expression of proadipogenic transcription factors such as PPARγ and C/EBPβ as well as lipogenic genes (Fig. 4AC ).
The antiadipogenic effect of C8-CPPC persisted after Rosiglitazone treatment ( 4D ).
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Pharmacological inhibition of DEGS1 also impairs adipocyte differentiation in vivo. We administered C8-CPPC IP to mice fed a HFD for 5weeks, an experimental protocol known to trigger adipocyte hyperplasia. Molecular analysis of the WAT from mice treated with C8-CPPC presented higher levels of pref-1+ cells, suggesting an increase in the number of preadipocytes vs. controls. Interestingly, a significant number of preadipocytes showed evidence of increased proliferation (Ki67+) whereas the number of differentiating preadipocytes (pref1+, bodipy +) was significantly smaller in comparison to controls (Fig.5A ). These data were reinforced at mRNA level by showing increased expression of pref-1 and gata2 ( Fig 5B) and the presence of less smaller adipocytes in treated mice (Fig.S6 ). Altogether, these data suggest C8-CPPC mediated inhibition of DEGS1 impaired the capacity of preadipocytes to differentiate into adipocytes in vivo.
DEGS1 is required for lipid accumulation, basal lipolysis and glucose uptake in mature adipocytes.
We next focused on the effects of DEGS1 inhibition in fully differentiated adipocytes by treating isolated mature adipocytes-from the gonadal adipose tissue of C57BL/6 mice-with C8-CPPC for 24h. C8-CPPC caused a decrease in the expression of lipid metabolism genes as well as an increase in antioxidant genes (Fig S7) recapitulating our observations in 3T3L1 preadipocytes.
We further investigated the effects of inhibiting DEGS1 on lipolytic activity and insulin signalling, and measured adiponectin expression as a representative fingerprint of global adipocyte homeostasis in mature differentiated 3T3L1 adipocytes. Thus, we observed that basal lipolytic activity was decreased in mature differentiated 3T3L1 adipocytes Ser565 was also substantially increased by C8-CPPC concomitantly with a minor downregulation of Ser660 phosphorylation (Fig.6B-D) suggesting a decreased HSL activity. Moreover, total levels of HSL were also decreased in C8-CPPC treated cells.
These data suggest that pharmacological inhibition of DEGS1 in mature adipocytes disrupts the lipolytic response under non-stimulated conditions a defect that was superseded in the presence of NA.
Finally we characterised the effects of pharmacological inhibition of DEGS1 on insulin signalling in 3T3-L1 mature adipocytes treated with C8-CPPC for 48h as described above, and subsequently incubated in the presence of increasing doses of insulin. No major differences where observed in the phosphorylation of AKT in C8-CPPC treated cells after acute insulin stimulation (Fig.6E) . However, we found that Glut4 protein levels were increased in C8-CPPC treated cells, suggesting that glucose uptake may be increased (Fig.6F) . Interestingly, we also did not observe any differences in either adiponectin levels in response to C8-CPPC or in AMPK phosphorylation, a known inducer of adiponectin, although increased levels of tAMPK were observed (Fig 6GH) .
Both, Pharmacological and Genetic inhibition of DEGS1 increases dihydroceramide/ceramide ratio in 3T3-L1-cells.
We confirmed that C8-CPPC increased the DhCer/Cer ratio in 3T3L-1 preadipocytes upon inhibition of DEGS1 (Fig.4E) . Similarly, degs1KD preadipocytes (d0) exhibited an increased DhCer/Cer ratio vs. controls. Downregulation of degs1 expression in degs1KD cells was accompanied by a dowregulation of serine palmitoyltransferase
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(sptlc1) and Ceramide synthase 6 (Cers6), suggestive of a homeostatic readjustment of the biosynthetic pathway to compensate for the dysfunction of degs1. Other genes related to ceramide homeostasis such as neutral ceramidase (ncdase), and glycosylceramide synthase (gcs) were also downregulated.
Curiously, at d9, degs1KD cells, despite impaired differentiation, showed a complete restoration of the DhCer/Cer ratio (indicated by the normalization of the ceramide pool) (Fig.S8A ). This could be partially explained by a compensation mechanism, mediated by downregulation of neutral ceramidases and the conversion of sphyngomyelins to ceramides (upregulation of sphyngomyelinase 2) (Fig.S8B ).
The Impairment of adipocyte differentiation during early adipogenesis by DEGS1 inhibition is recapitulated by Dihydroceramides per se.
We finally sought to validate whether DhCer by itself could mediate the effects of DEGS1 inhibition on adipocyte differentiation in our models of genetic or pharmacological inhibition of degs1. 3T3-L1cells were treated with C2-DhCer during a) the MCE at time 0 and b) at day 3 after differentiation. DhCer inhibited lipid accumulation (Fig.7A ) and the expression of genes involved during the early stages of adipogenesis (Fig. 7B ).
Since synthetic sphingolipid analogues are known to modulate PPARs activity(22), we investigated whether both C2 and C16 DhCer could exert a repressive effect on PPARγ activation in the presence of the PPARγ ligands (Fig. 7C) . Our results show that DhCer can also block the ligand-mediated transactivation of PPARγ. Similar results were obtained with ceramides, indicating these effects were not a consequence of the unsaturation of the sphingoid moiety (data not shown).
DISCUSSION
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The DhCer/Cer ratio has an important homeostatic regulatory role in the cell, contributing to cell survival, autophagy and oxidative stress (12; 13 (25) . Globally considered, these data suggest the existence of an association between DEGS1 function and fat mass.
The molecular mechanism leading to the defective adipose tissue expression of degs1 in human and rodent obesity is unknown. Here, we have shown that TNFα, a mediator of obesity induced inflammation and insulin resistance, decreases the transcriptional expression of degs1 in cultured adipocytes, which suggests that low chronic inflammation may contribute to DEGS1 dysfunction. Other obesity associated processes, such as increased oxidative stress and hypoxia, have been shown to impair DEGS1 activity and increase DhCer levels (26) . Our results also show a positive association between levels of the proadipogenic pparγ2 isoform and degs1 in adipose Our in vitro studies revealed that the defect in adipogenesis programme caused by depletion of DEGS1 occurs during the early stages of adipogenesis (MCE) when PPARγ controls the expression of genes that regulate the cell cycle, by directly interacting with cyclin D3. Another cyclin involved in adipocyte differentiation is cyclin D1, and here we show that downregulation of DEGS1 blocks PPARγ activity and cyclins such as D1, D3, E, as well as decreasing cdk2, which modulates PPARγ activity during adipogenesis. These data are consistent with studies showing that downregulation of degs1 by siRNA inhibits cell growth and arrests the cell cycle in cancer cells (12) , and where its overexpression increased cell migration and metastasis (27) .
The pharmacological inhibition of DEGS1 in vivo validated the results obtained in vitro and strengthen the concept that functional degs1 is required for the full differentiation of preadipocytes into mature adipocytes.
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We also provide evidence that both pharmacological and genetic ablation of degs1 certainly increased DhCer levels in in vitro models which according to our results in in vitro models may directly block adipocyte differentiation and lipid deposition. This effect on lipid accumulation was more severe when the treatment was administered during the first three days of differentiation, suggesting a direct impact of DhCer accumulation during early stages of adipogenesis. We also provide evidence showing that accumulation of DhCers can also directly repress the transcriptional activity of PPARγ and hence could contribute to impair the capacity of the preadipocytes to develop a full adipogenic programme.
These observations strengthen the concept that DhCers are not merely inert precursors of ceramides. Nevertheless, the molecular mechanism linking DhCers accumulation and dysregulation of the cell cycle and other cellular events remains elusive. One possible mechanism is that changes in the DhCer/Cer ratio may disrupt membrane dependent structures by altering the levels of cholesterol and/or caveolin in lipid rafts, which are known to be highly sensitive to sphingomyelin pool. Alternatively, changes in the DhCer/Cer ratio may disturb the global phospholipidome, potentially altering membrane-associated processes relevant to adipocyte function. These are important questions to address in future research.
In summary, our results indicate that defects in DEGS1 in the context of the MetS may compromise adipose tissue expansion and function through the combined inhibition of adipogenesis, promotion of cell death and oxidative stress due to the direct accumulation of DhCers. Thus, our data suggests that the selective manipulation of DEGS1 and/or its substrates in WAT may be a pathophysiologically advantageous 
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